Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 3 , Pages 137-149 , September 2006

Adaptations of nanoscale viruses and other protein cages for medical applications

  • L. Andrew Lee, BSc
    • ,
  • Qian Wang, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Chemistry & Biochemistry and Nanocenter, University of South Carolina, Columbia, SC 29208.

Received 29 June 2006 ,Accepted 19 July 2006.

References 

  1. Niemeyer CM. Nanoparticles, protein, and nucleic acids: Biotechnology meets materials science. Angew Chem Int Ed. 2001;40:4128–4158
  2. Dujardin E, Mann S. Bio-inspired materials chemistry. Adv Eng Mater. 2002;4:461–474
  3. Seeman NC. At the crossroads of chemistry, biology, and materials: Structural DNA nanotechnology. Chem Biol. 2003;10:1151–1159
  4. Shih WM, Quispe JD, Joyce GF. A 1.7-kilobase single-stranded DNA that folds into a nanoscale octahedron. Nature. 2004;427:618–621
  5. Georgens C, Weyermann J, Zimmer A. Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol. 2005;6:49–55
  6. Muller OJ, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003;21:1040–1046
  7. Peng KW, et al. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther. 2004;11:1234–1239
  8. May T, Gleiter S, Lilie H. Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J Virol Methods. 2002;105:147–157
  9. Kramer RM, et al. Engineered protein cages for nanomaterial synthesis. J Am Chem Soc. 2004;126:13282–13286
  10. Ensign D, Young M, Douglas T. Photocatalytic synthesis of copper colloids from Cu(II) by the ferrihydrite core of ferritin. Inorg Chem. 2004;43:3441–3446
  11. Hosein HA, et al. Iron and cobalt oxide and metallic nanoparticles prepared from ferritin. Langmuir. 2004;20:10283–10287
  12. Flenniken ML, et al. The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification. Nano Lett. 2003;3:1573–1576
  13. Flenniken ML, et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb). 2005;447–449
  14. Flenniken ML, et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol. 2006;13:161–170
  15. Raja KS, Wang Q. Bionanoparticles and Nanotechnology. In:  Schwarz JA,  Contescu CI,  Putyera K editor. Encyclopedia of Nanoscience and Nanotechnology, Vol. B. New York: Marcel Dekker; 2004;p. 321–330
  16. Seebeck FP, et al. A simple tagging system for protein encapsulation. J Am Chem Soc. 2006;128:4516–4517
  17. Rai P, et al. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotechnol. 2006;24:582–586
  18. Hodge JW, et al. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst. 2000;92:1228–1239
  19. Hodge JW, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59:5800–5807
  20. Bachmann MF, et al. The influence of antigen organization on B-cell responsiveness. Science. 1993;262:1448–1451
  21. Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol. 1998;161:5791–5794
  22. Wong KKW, et al. Biomimetic synthesis and characterization of magnetic proteins (magnetoferritin). Chem Mater. 1998;10:279–285
  23. Douglas T, Stark VT. Nanophase cobalt oxyhydroxide mineral synthesized within the protein cage of ferritin. Inorg Chem. 2000;39:1828–1830
  24. Paavola C, et al. A versatile platform for nanotechnology based on circular permutation of a chaperonin protein. Nanotechnology. 2006;17:1171–1176
  25. Kerfeld CA, et al. Protein structures forming the shell of primitive bacterial organelles. Science. 2005;309:936–938
  26. Verheije MH, et al. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J Virol. 2006;80:1250–1260
  27. Shin YC, Folk WR. Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor. J Virol. 2003;77:11491–11498
  28. Gleiter S, Lilie H. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol Chem. 2003;384:247–255
  29. Lomonossoff GP, Johnson JE. Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Curr Opin Struct Biol. 1996;6:176–182
  30. Lomonossoff GP, Hamilton WDO. Cowpea mosaic virus-based vaccines. Curr Top Microbiol Immunol. 1999;240:177–189
  31. Arvin AM, Greenberg HB. New viral vaccines. Virology. 2006;344:240–249
  32. Navarro J, et al. Gene delivery systems: bridging the gap between recombinant viruses and artificial vectors. Adv Drug Deliv Rev. 1998;30:5–11
  33. Young LS, et al. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006;208:299–318
  34. Wang Q, et al. Blue fluorescent antibodies as reporters of steric accessibility in virus conjugates. Bioconjug Chem. 2003;14:38–43
  35. Wang Q, et al. Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed Engl. 2002;41:459–462
  36. Wang Q, et al. Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem Biol. 2002;9:813–819
  37. Wang Q, et al. Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol. 2002;9:805–811
  38. Raja KS, et al. Hybrid virus-polymer materials. 1. Synthesis and Properties of PEG-decorated cowpea mosaic virus. Biomacromolecules. 2003;4:472–476
  39. Strable E, Johnson JE, Finn MG. Natural nanochemical building blocks: icosahedral virus particles organized by attached oligonucleotides. Nano Lett. 2004;4:1385–1389
  40. Chatterji A, et al. Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Intervirology. 2002;45:362–370
  41. Raja KS, Wang Q, Finn MG. Icosahedral virus particles as polyvalent carbohydrate display platforms. Chembiochem. 2003;4:1348–1351
  42. Sen Gupta S, et al. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem. 2005;16:1572–1579
  43. Gillitzer E, et al. Chemical modification of a viral cage for multivalent presentation. Chem Commun (Camb). 2002;2390–2391
  44. Taylor D, et al. Correlation of chemical reactivity of Nudaurelia capensis omega virus with a pH-induced conformational change. Chem Commun (Camb). 2003;2770–2771
  45. Schlick TL, et al. Dual-surface modification of the tobacco mosaic virus. J Am Chem Soc. 2005;127:3718–3723
  46. Barnhill HN, et al. Dual modification of turnip yellow mosaic virus: synthesis of a biotinylated luminescent nanoparticle. In: Proceedings of the 231st American Chemical Society National Meeting, Atlanta, GA, March 26-30, 2006. Polymer and material science engineering (PMSE). 2006;
  47. Soto CM, et al. Fluorescent signal amplification of carbocyanine dyes using engineered viral nanoparticles. J Amer Chem Soc. 2006;128:5184–5189
  48. Hooker JM, Kovacs EW, Francis MB. Interior surface modification of bacteriophage MS2. J Am Chem Soc. 2004;126:3718–3719
  49. Peabody DS. A viral platform for chemical modification and multivalent display. J Nano Bio Tech. 2003;1:5
  50. Mammen M, Choi S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl. 1998;37:2754–2794
  51. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. Science. 2005;310:1139–1143
  52. Jeong KJ, Mabry R, Georgiou G. Avimers hold their own. Nat Biotechnol. 2005;23:1493–1494
  53. Silverman J, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol. 2005;23:1556–1561
  54. Khor IW, et al. Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. J Virol. 2002;76:4412–4419
  55. Manchester M, et al. Measles virus recognizes its receptor, CD46, via two distinct binding domains within Scr1-2. Virology. 1997;233:174–184
  56. Manchester M, et al. Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A. 1994;91:2161–2165
  57. Oh IK, Mok H, Park TG. Folate immobilized and pegylated adenovirus for retargeting to tumor cells. Bioconjug Chem. 2006;17:721–727
  58. Lewis JD, et al. Viral nanoparticles as tools for intravital vascular imaging. Nat Med. 2006;12:354–360
  59. Weissleder R, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418–1423
  60. Smith AE, Lilie H, Helenius A. Ganglioside-dependent cell attachment and endocytosis of murine polyomavirus-like particles. FEBS Lett. 2003;555:199–203
  61. Sandalon Z, Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology. 1997;237:414–421
  62. Chang D, et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol. 1997;78:1435–1439
  63. Gillock ET, et al. Polyomavirus major capsid protein VP1 is capable of packaging cellular DNA when expressed in the baculovirus system. J. Virol. 1997;71:2857–2865
  64. Sasnauskas K, et al. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem. 1999;380:381–386
  65. Schmidt U, et al. Site-specific fluorescence labeling of recombinant polyomavirus-like particles. Biol Chem. 1999;380:397–401
  66. Ou WC, et al. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol. 1999;80:39–46
  67. Tsai B, et al. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 2003;22:4346–4355
  68. Caruso M, et al. α4β1 Integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J Virol. 2003;77:3913–3921
  69. Caruso M, et al. Role of sialic acid-containing molecules and the (4(1 integrin receptor in the early steps of polyomavirus infection. J Gen Virol. 2003;84:2927–2936
  70. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186:S180–S186
  71. Wang M, et al. Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther. 2004;15:1077–1090
  72. Yamada T, et al. Novel tissue and cell type-specific gene/drug delivery system using surface engineered hepatitis B virus nano-particles. Curr Drug Targets Infect Disord. 2004;4:163–167
  73. Yu D, et al. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J. 2005;272:3651–3660
  74. Yamada T, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003;21:885–890
  75. Gleiter S, Lilie H. Coupling of antibodies via protein Z on modified polyomavirus-like particles. Protein Sci. 2001;10:434–444
  76. Chatterji A, et al. New addresses on an addressable virus nanoblock; uniquely reactive Lys residues on cowpea mosaic virus. Chem Biol. 2004;11:855–863
  77. Chatterji A, et al. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem. 2004;15:807–813
  78. Wang Q, et al. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc. 2003;125:3192–3193
  79. Zhan WH, et al. Synthesis of hemicyanine dyes for “click” bioconjugation. Tetrahedron Lett. 2005;46:1691–1695
  80. Krauzewicz N, et al. Sustained ex vivo and in vivo transfer of a reporter gene using polyomavirus pseudocapsids. Gene Ther. 2000;7:1094–1102
  81. Touze A, et al. Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J Gen Virol. 2001;82:3005–3009
  82. Osterman JV, Waddell A, Aposhian HV. DNA and gene therapy: uncoating of polyoma pseudovirus in mouse embryo cells. Proc Natl Acad Sci U S A. 1970;67:37–40
  83. Kimchi-Sarfaty C, Gottesman MM. SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr Pharm Biotechnol. 2004;5:451–458
  84. Kimchi-Sarfaty C, et al. In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther. 2002;13:299–310
  85. Kimchi-Sarfaty C, et al. High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther. 2003;14:167–177
  86. Krauzewicz N, et al. Virus-like gene transfer into cells mediated by polyomavirus pseudocapsids. Gene Ther. 2000;7:2122–2131
  87. Kimchi-Sarfaty C, et al. Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum Gene Ther. 2005;16:1110–1115
  88. Rae CS, et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology. 2005;343:224–235
  89. Ewers H, et al. Single-particle tracking of murine polyoma virus-like particles on live cells and artificial membranes. Proc Natl Acad Sci U S A. 2005;102:15110–15115
  90. Wu C, et al. A new probe using hybrid virus-dye nanoparticles for near-infrared fluorescence tomography. Opt Commun. 2005;255:366–374
  91. Medintz IL, et al. Decoration of discretely immobilized cowpea mosaic virus with luminescent quantum dots. Langmuir. 2005;21:5501–5510
  92. Chatterji A, et al. A virus-based nanoblock with tunable electrostatic properties. Nano Lett. 2005;5:597–602
  93. Portney NG, et al. Organic and inorganic nanoparticle hybrids. Langmuir. 2005;21:2098–2103
  94. Blum AS, et al. An engineered virus as a scaffold for three-dimensional self-assembly on the nanoscale. Small. 2005;1:702–706
  95. Souza GR, et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci U S A. 2006;103:1215–1220
  96. Schmidt U, et al. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J. 2001;15:1646–1648
  97. Abbing A, et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem. 2004;279:27410–27421
  98. Johnson J, Lin T, Lomonossoff G. Presentation of heterologous peptides on plant viruses: genetics, structure, and function. Annu Rev Phytopathol. 1997;35:67–86
  99. Dalsgaard K, et al. Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol. 1997;15:248–252
  100. Langeveld JP, et al. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine. 2001;19:3661–3670
  101. Marusic C, et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol. 2001;75:8434–8439
  102. Yusibov V, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002;20:3155–3164
  103. Koo M, et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A. 1999;96:7774–7779
  104. Smith ML, et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 2006;348:475–488
  105. Brennan FR, et al. A chimaeric plant virus vaccine protects mice against a bacterial infection. Microbiology. 1999;145:2061–2067
  106. Brennan FR, et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology. 1999;145:211–220
  107. Rennermalm A, et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine. 2001;19:3376–3383
  108. Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278
  109. Villa LL, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571–5583
  110. Chen XS, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5:557–567
  111. Harding JA, et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327:181–192
  112. Xu ZL, et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev. 2005;57:781–802
  113. Croyle MA, et al. Pegylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 2002;13:1887–1900
  114. Singh P, Gonzalez MJ, Manchester M. Viruses and their uses in nanotechnology. Drug Dev Res. 2006;67:23–41
  115. Dirksen A, et al. A supramolecular approach to multivalent target-specific MRI contrast agents for angiogenesis. Chem Commun (Camb). 2005;2811–2813
  116. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 2005;57:2271–2286

 No financial conflict of interest was reported by the authors of this paper.

PII: S1549-9634(06)00107-9

doi: 10.1016/j.nano.2006.07.009

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 3 , Pages 137-149 , September 2006

Article Tools

* Image Usage & Resolution